|
시장보고서
상품코드
2003600
햄스터 난소 응고인자 시장 규모, 점유율 및 성장 분석 : 제품 유형별, 발현 시스템 기술별, 제조 프로세스별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Hamster Ovary Clotting Factors Market Size, Share, and Growth Analysis, By Product Type, By Expression System Technology, By Manufacturing Process, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 햄스터 난소(CHO) 응고인자 시장 규모는 2024년에 20억 달러로 평가되며, 2025년 21억 6,000만 달러에서 2033년까지 40억 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 8.0%로 성장할 것으로 전망되고 있습니다.
세계의 햄스터 난소(CHO) 응고인자 시장은 주로 혈장 유래 농축 제제에서 CHO 세포에서 생산되는 재조합 단백질로 전환하여 치료의 안전성과 규제 준수를 향상시킴으로써 시장을 주도하고 있습니다. 이 시장에는 혈우병 및 관련 출혈성 질환에 대한 재조합 제8인자 및 제9인자 치료제가 포함되며, 분자 공학을 통해 반감기와 효능을 향상시키는 동시에 병원체 전파 위험을 크게 줄였다. 개발은 확장 가능한 바이오프로세스로 전환하고 있으며, CHO 세포 공학 및 다운스트림 프로세스 개선에 대한 투자가 촉진되고 있습니다. 이를 통해 수율을 높이고 비용을 절감할 수 있습니다. 그 결과, 예방적 사용이 확대되고 입원율이 감소하고 있습니다. 또한 AI 기술은 세포주 개발의 효율성을 높이고, 제품의 균일성을 보장하여 생산성을 향상시키고, 제조 공정의 전환을 가속화하고, 공정의 신뢰성을 높이는 데 중요한 역할을 하고 있습니다. 이는 이러한 치료법에 대한 수요가 증가하고 있다는 점을 감안할 때 특히 중요한 의미를 지닙니다.
세계의 햄스터 난소(CHO) 응고 인자 시장의 성장 요인
세계의 햄스터 난소(CHO) 응고인자 시장은 일관된 제품 품질과 확장성을 제공할 수 있다는 점에서 제조업체와 의료 서비스 제공자 사이에서 CHO 세포 유래 재조합 응고인자에 대한 선호도가 높아지면서 수혜를 받고 있습니다. 이를 통해 인간 혈장에 대한 의존도를 낮추고, 공급 안정성을 향상시켜 환자의 안전을 보장합니다. 이러한 장점은 전용 제조 능력과 장기 계약에 대한 투자를 촉진할 뿐만 아니라 광범위한 상업화 및 시장 성장을 촉진할 수 있습니다. 제조업체들이 CHO 시스템과 관련된 예측 가능한 당쇄 프로파일을 달성하고 엄격한 공정 관리에 집중함에 따라 CHO 기반 바이오의약품의 개발이 활발해질 것으로 예상되며, 이는 응고인자 제품의 지속적인 시장 확대를 더욱 촉진할 것으로 보입니다.
세계의 햄스터 난소(CHO) 응고 인자 시장 억제요인
세계의 햄스터 난소(CHO) 응고인자 시장은 복잡한 제조 방법과 엄격한 규제 요건으로 인해 전문 시설과 전문 지식이 필요하므로 큰 제약 요인에 직면해 있습니다. 이러한 요인들은 제조업체에 큰 재정적 부담을 주며, 기업이 전용 생산능력에 대한 투자를 주저하게 만들어 공급확대를 저해하고 시장 경쟁력을 떨어뜨릴 수 있습니다. 또한 막대한 초기 투자 비용과 지속적인 규제 준수 의무는 기업이 제품 포트폴리오를 다양화할 수 있는 능력을 제한하고, 상용화까지 걸리는 시간을 연장시킬 수 있습니다. 이러한 환경은 특히 소규모 생산자나 자원에 제약이 있는 생산자에게는 시장 진입의 위험을 높이고, 기술 발전을 복잡하게 만들어 전체 시장의 성장을 저해하는 요인으로 작용할 수 있습니다.
세계의 햄스터 난소(CHO) 응고인자 시장 동향
세계의 햄스터 난소(CHO) 응고인자 시장에서는 제조업체들이 생산성을 최적화하고 워크플로우의 효율성을 높이는 데 중점을 두면서 바이오 공정의 집약화 추세가 두드러지게 나타나고 있습니다. 세포주 최적화, 관류 전략, 일회용 기술 등 첨단 기법을 도입하는 방향으로의 전환이 두드러지게 나타나고 있으며, 이는 모두 개발을 가속화하면서 제품의 균일성을 높이는 것을 목표로 하고 있습니다. 또한 위탁개발기관(CDO)과의 전략적 제휴와 자동화 및 디지털 모니터링에 대한 투자가 일반화되고 있으며, 이를 통해 신속한 프로세스 검증이 가능해져 규제 표준을 준수할 수 있게 되었습니다. 이러한 진화하는 상황은 치료 수요에 대한 대응력을 향상시키고, 업무의 복잡성을 감소시킬 뿐만 아니라, 우수한 공급 체계와 품질 특성을 통해 경쟁적 차별화를 촉진합니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 햄스터 난소 응고인자 시장 규모 : 제품 유형별
세계의 햄스터 난소 응고인자 시장 규모 : 발현 시스템 기술별
세계의 햄스터 난소 응고인자 시장 규모 : 제조 프로세스별
세계의 햄스터 난소 응고인자 시장 규모 : 최종사용자별
세계의 햄스터 난소 응고인자 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.04.28Global Hamster Ovary (Cho) Clotting Factors Market size was valued at USD 2.0 Billion in 2024 and is poised to grow from USD 2.16 Billion in 2025 to USD 4.0 Billion by 2033, growing at a CAGR of 8.0% during the forecast period (2026-2033).
The Global Hamster Ovary (CHO) clotting factors market is primarily driven by the transition from plasma-derived concentrates to recombinant proteins manufactured in CHO cells, enhancing therapeutic safety and regulatory compliance. This market includes recombinant Factor VIII and IX therapies for hemophilia and related bleeding disorders, significantly lowering pathogen transmission risks while facilitating advancements in half-life and efficacy through molecular engineering. Development has shifted towards scalable bioprocesses, promoting investment driven by improved CHO cell engineering and downstream processing, which enhance yield and reduce costs. This results in expanded prophylactic use, decreasing hospitalization rates. Additionally, AI technology plays a crucial role in boosting productivity by streamlining cell line development and ensuring product consistency, leading to faster manufacturing transitions and improved process reliability, particularly relevant given the increasing demand for these therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hamster Ovary (Cho) Clotting Factors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hamster Ovary (Cho) Clotting Factors Market Segments Analysis
Global hamster ovary (cho) clotting factors market is segmented by product type, expression system technology, manufacturing process, end-user and region. Based on product type, the market is segmented into Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor (vWF). Based on expression system technology, the market is segmented into Standard CHO-K1/DG44 Derived and Glyco-engineered CHO Lines. Based on manufacturing process, the market is segmented into Fed-batch Culture and Continuous Perfusion Bioprocessing. Based on end-user, the market is segmented into Pharmaceutical Companies, Biopharma CDMOs and Research & Clinical Trial Units. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Hamster Ovary (Cho) Clotting Factors Market
The Global Hamster Ovary (CHO) Clotting Factors market benefits from the increasing preference for CHO cell-derived recombinant clotting factors among manufacturers and healthcare providers due to their ability to deliver consistent product quality and scalability. This reduces dependence on human plasma, enhancing supply stability and ensuring patient safety. Such advantages not only spur investment in dedicated manufacturing capabilities and long-term contractual agreements but also facilitate broader commercialization and market growth. As manufacturers focus on achieving predictable glycosylation profiles and exercising stringent process control associated with CHO systems, the development of CHO-based biologics is likely to flourish, further promoting sustained market expansion for clotting factor products.
Restraints in the Global Hamster Ovary (Cho) Clotting Factors Market
The Global Hamster Ovary (CHO) Clotting Factors market faces significant restraints due to intricate production methodologies and rigorous regulatory requirements, which necessitate specialized facilities and expertise. These factors impose considerable financial burdens on manufacturers, potentially deterring organizations from investing in dedicated production capabilities, consequently hindering supply expansion and reducing market competitiveness. Additionally, substantial initial setup costs and continuous compliance obligations can restrict the ability of companies to diversify their product portfolios and extend commercialization timelines. This environment creates higher risks for market entry and complicates technological advancements, particularly for smaller or resource-constrained producers, thereby impeding overall market growth.
Market Trends of the Global Hamster Ovary (Cho) Clotting Factors Market
The Global Hamster Ovary (CHO) Clotting Factors market is witnessing a significant trend towards bioprocess intensification as manufacturers emphasize optimizing productivity and streamlining workflows. There is a pronounced shift towards implementing advanced methods such as cell line optimization, perfusion strategies, and single-use technologies, all aimed at enhancing product consistency while expediting development. Additionally, strategic collaborations with contract development organizations and investments in automation and digital monitoring are becoming prevalent, enabling rapid process validation and ensuring compliance with regulatory standards. This evolving landscape not only improves responsiveness to therapeutic demands and reduces operational complexities but also fosters competitive differentiation through superior supply and quality attributes.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Hamster Ovary (CHO) Clotting Factors Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Recombinant Factor VIII
- Recombinant Factor IX
- Von Willebrand Factor (vWF)
Global Hamster Ovary (CHO) Clotting Factors Market Size by Expression System Technology & CAGR (2026-2033)
- Market Overview
- Standard CHO-K1/DG44 Derived
- Glyco-engineered CHO Lines
Global Hamster Ovary (CHO) Clotting Factors Market Size by Manufacturing Process & CAGR (2026-2033)
- Market Overview
- Fed-batch Culture
- Continuous Perfusion Bioprocessing
Global Hamster Ovary (CHO) Clotting Factors Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Pharmaceutical Companies
- Biopharma CDMOs
- Research & Clinical Trial Units
Global Hamster Ovary (CHO) Clotting Factors Market Size & CAGR (2026-2033)
- North America (Product Type, Expression System Technology, Manufacturing Process, End-User)
- US
- Canada
- Europe (Product Type, Expression System Technology, Manufacturing Process, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Expression System Technology, Manufacturing Process, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Expression System Technology, Manufacturing Process, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Expression System Technology, Manufacturing Process, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Takeda
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Octapharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cytiva
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Diosynth
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
